CCM
ORIC icon

CAAS Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

CAAS Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,500
Closed -$422K – 567
2020
Q2 		$422K Buy
+12,500
New +$399K 0.01% 327

Other funds holding ORIC

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's ORIC Position: Q3 2020 in Review

CAAS Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q3 2020, closing a stake of 12,500 shares — an estimated $422K sold.

CAAS Capital Management first reported a position in ORIC in Q2 2020 and held it in 1 quarter. The position peaked at $422K in Q2 2020. 54 funds tracked by Wall St. Rank hold ORIC as of Q3 2020.

  • CAAS Capital Management reported no remaining Oric Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 12,500 Oric Pharmaceuticals shares in Q3 2020, an estimated $422K.
  • CAAS Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Oric Pharmaceuticals position peaked at $422K in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.